Global Rosuvastatin Market Insights Forecasts to 2033  

• The Global Rosuvastatin Market Size was Estimated at USD 3.36 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 3.80% from 2023 to 2033
• The Worldwide Rosuvastatin Market Size is Expected to Reach USD 4.88 Billion by 2033
• Asia Pacific is expected to grow at the fastest region during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Rosuvastatin Market Size is predicted to exceed USD 4.88 billion by 2033, growing at a CAGR of 3.80% from 2023 to 2033. The global rosuvastatin market is fueled by rising cardiovascular disease prevalence, and growing awareness about heart-related health issues, mostly prescribed drugs by healthcare physicians and the aging population. Top of Form

 

Market Overview           

The global rosuvastatin market aims to develop, produce, and distribute drugs that are primarily used to lower cholesterol levels and minimize the risk of cardiovascular diseases. Rosuvastatin referred to as Crestor, is a statin drug used to treat cardiovascular disease and manage lipids in high-risk individuals. Its unique properties, low extrahepatic tissue penetration, and LDL-C lowering capacity make it effective.  

 

According to the World Health Organization (WHO), it is reported that 39% of the adult population is influenced by elevated cholesterol levels, with women having a higher prevalence of 40%. In 2019, as per the World Health Survey in Saudi Arabia, the urban and rural areas had higher occurrences of hyperlipidaemic conditions as compared to wealthier individuals.  

 

Several Government initiatives drive the demand for the rosuvastatin drug in the market. For instance, The Therapeutic Lifestyle Changes (TLC) Program, developed by the National Heart, Lung, and Blood Institute, aims to enhance cholesterol levels through a diet plan and therapeutic agents.

 

Government organizations such as WHO, FDA, and other regulatory bodies are focusing on decreasing the mortality rate associated with cardiovascular disease including hyperlipidaemic disease. For example, The World Health Organization's Global Action Plan aimed to reduce cardiovascular disease (CVD) mortality and prevent heart attacks and strokes. It highlighted the importance of lipid-lowering therapy for adults aged 40-79.

 

The market growth is driven by the establishment of government initiatives, innovations in drug discovery, growth in the pharmaceutical research and development sector, and increasing awareness regarding hyperlipidaemic therapeutics.

 

Report Coverage

This research report categorizes the global rosuvastatin market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global rosuvastatin market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global rosuvastatin market.

 

Driving Factors:

Proliferation of cardiovascular diseases:

The worldwide demand for rosuvastatin is being driven by the rising incidence of cardiovascular diseases (CVD) brought on by unhealthy lifestyles, poor food, smoking, and inactivity. It is a powerful statin that lowers LDL cholesterol, which is a risk factor for heart disease, and the burden is increased as the population ages.

 

Geriatric population:

One of the main factors driving the rosuvastatin market is the geriatric population, which is at a higher risk of developing chronic illnesses as wear and tear of the arteries and blood vessels occurs. Older individuals with high cholesterol are ideal candidates for statin treatment. Market expansion is supported by the increased prevalence of integrated therapies like rosuvastatin due to demographic shifts and other health conditions.

 

Restraining Factors

The patent expiration of rosuvastatin has led to the introduction of generic versions, potentially reducing brand-name revenue and affecting market dynamics due to reimbursement policy variations.

 

Market Segmentation

The global rosuvastatin market share is classified into formulation type, dose strength, indication, and distribution channel.

 

• The tablets accounted for the largest share in 2023 and is anticipated to grow at a CAGR of 3.28% during the projected timeframe.

Based on the formulation type, the global rosuvastatin market is categorized as injectables, tablets, and oral suspension. Among these, the tablets accounted for the largest share in 2023 and is anticipated to grow at a CAGR of 3.28% during the projected timeframe. The segmental growth is driven by greater stability, more cost-effective than injectables, ease of administration for patients, innovations in the production methodology of tablets including sustained-release tablets which release the drug slowly and have a longer shelf life with prolonged specific therapeutic effect, patient adherence, widely prescribed dosage form by doctors and healthcare professionals, avoidance of dosing errors, self-governance, children and aged population prefer tablets as unpleasant taste is masked by sugar coating, less invasive, and most suitable dosage form for trypanophobia patients.

 

• The 10mg and 20mg segment held a substantial share in 2023 and is expected to grow at a significant CAGR during the estimated period.

Based on the dose strength, the global rosuvastatin market is categorized as 5mg, 10mg, 20mg, and 40mg. Among these, the 10mg and 20mg segment held a substantial share in 2023 and is expected to grow at a significant CAGR during the estimated period. The segmental expansion is attributed to several factors including a 10 mg dose of rosuvastatin is more efficacious, enhancing the lipid metabolism, and a 20 mg dose of rosuvastatin is prescribed to patients having specific types of genotypes and it avoids adverse effects and increases the exposure of the drug. The segment growth is additionally driven by the ability to balance safety and efficacy and further developments in pharmaceuticals may increase their adaptability.

 

• The hyperlipidemia segment dominated the global rosuvastatin market in 2023 and is predicted to grow at a significant CAGR during the predicted timeframe.

Based on the indication, the global rosuvastatin market is categorized as cardiovascular disease, atherosclerosis, and hyperlipidemia. Among these, the hyperlipidemia segment dominated the global rosuvastatin market in 2023 and is predicted to grow at a significant CAGR during the predicted timeframe. The segment growth is ascribed to lack of exercise, increasing incidence of lipid disorders, obesity, inadequate nutrition, global emphasis on preventive healthcare and government initiatives addressing lifestyle-related diseases, high intake of saturated fatty acids, innovations in the treatment, older adult population. Additionally, several factors including smoking, and insulin resistance drive the segment growth.

 

• The hospital pharmacy segment accounted for the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted timeframe.

Based on the distribution channel, the global rosuvastatin market is categorized as retail pharmacy, hospital pharmacy, and online pharmacy. Among these, the hospital pharmacy segment accounted for the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted timeframe. This sector growth is owing to the provisions of specialized care, immediate access to patients receiving treatment, availability of drug monitoring services, provision of medicines in emergencies, and compounding medication with counselling facilities.

 

Regional Segment Analysis of the Global Rosuvastatin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global rosuvastatin market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is anticipated to hold the largest share of the global rosuvastatin market over the predicted timeframe. The healthcare system in North America is well-established, with a large number of clinics, hospitals, and pharmacies. Individuals with fatal cardiovascular diseases and hyperlipidemia can easily obtain these medications Furthermore, the region's high prevalence of cardiovascular disorders is fueling the rosuvastatin market's expansion.

 

Asia Pacific is expected to be the fastest-growing region of the global rosuvastatin market during the forecast period. The region's growing medical infrastructure, high population, and significant patient base are the outcomes of sustainability. The market is predicted to be driven by several initiatives implemented by the government and top healthcare organizations to mitigate the prevalence of cardiovascular illnesses throughout the area.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global rosuvastatin market along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Lunan Pharmaceutical
• Teva Pharmaceuticals
• Niksan Pharmaceutical
• JB Pharma
• MSN Laboratories
• Glenmark Pharmaceuticals Inc.
• Nextwell Pharmaceutical
• Pfizer
• Torrent Pharmaceuticals
• Mylan Laboratories
• Lupin Pharmaceuticals
• Sun Pharmaceuticals
• Hikma Pharmaceuticals
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

• In January 2025, as per the data published in the Australian Prescriber, it was revealed that from July 2023 to June 2024, Rosuvastatin and Atorvastatin were the most prescribed drugs under the Pharmaceutical Benefits Schedule and Repatriation Pharmaceutical Benefits Scheme, with over 80 people per 1000 taking a standard dose daily.

 

• In July 2024, Cinfa a European pharmaceutical laboratory launched its novel product Rosvacor (Rosuvastatin) in Qatar. Cinfa's cardiometabolic expansion has reached a significant milestone, offering new therapeutic options for dyslipidemia and cardiovascular disease prevention, with Rosvacor available in doses of 5mg, 10mg, and 20mg.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global rosuvastatin market based on the below-mentioned segments:

 

Global Rosuvastatin Market, By Formulation Type

• Injectables
• Tablets
• Oral Suspension

 

Global Rosuvastatin Market, By Dose Strength

• 5mg
• 10mg
• 20mg
• 40mg

 

Global Rosuvastatin Market, By Indication

• Cardiovascular Diseases
• Atherosclerosis
• Hyperlipidemia

 

Global Rosuvastatin Market, By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

 

Global Rosuvastatin Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa